冷冻球囊肺静脉隔离作为典型心房扑动一线治疗
本研究为国际多中心随机对照试验,纳入113例无房颤记录的典型房扑患者,比较冷冻球囊PVI与射频CTI消融作为一线治疗的效果。主要终点为12个月内持续症状性房性心律失常复发,两组无显著差异(HR 1.11,95%CI 0.46-2.67),但PVI组新发房颤≥2分钟的风险显著降低(HR 0.46,95%CI 0.25-0.85)。
要点
- 冷冻球囊PVI与CTI消融在预防房性心律失常复发方面效果相当。
- 冷冻球囊PVI可显著减少新发房颤≥2分钟的发生风险。
- 两组复合安全终点事件无显著差异。
核心结论
- 冷冻球囊PVI作为典型房扑一线治疗在预防房性心律失常复发方面与标准CTI消融等效,且更优地预防新发房颤。
研究设计与样本
- 国际多中心、开放标签、盲法评估的随机对照试验,因SARS-CoV-2疫情提前终止,最终纳入113例(目标130例)CTI依赖性房扑且无房颤记录的患者,随机分为冷冻球囊PVI组(n=59)和射频CTI消融组(n=54)。
主要发现
- 12个月时主要疗效终点(持续>30秒的症状性房性心律失常复发)在PVI组发生11例(18.6%),CTI组9例(16.7%),无显著差异(HR 1.11,95%CI 0.46-2.67)。
- 房扑复发在PVI组6例(10.2%),CTI组1例(1.9%)(p=0.116)。
- ≥2分钟房颤发生时间在冷冻球囊PVI组显著缩短(HR 0.46,95%CI 0.25-0.85)。
- 复合安全终点事件PVI组4例,CTI组3例(p=1.000)。
关键数值与推荐
- 主要疗效终点:12个月内持续>30秒的症状性房性心律失常(房颤/房扑/房速)首次复发时间,通过植入式循环记录仪连续监测评估。
- 主要安全终点:死亡、卒中、需引流的心包填塞、房食管瘘、起搏器植入、严重血管并发症或持续性膈神经麻痹的复合终点。
临床怎么用
- 对于无房颤记录的典型房扑患者,冷冻球囊PVI可作为CTI消融的替代一线策略,尤其有助于减少新发房颤。
局限性
- 因SARS-CoV-2疫情提前终止,样本量未达目标,可能影响统计效能。
- 开放标签设计,但主要终点采用盲法评估。
- 研究人群以男性为主(86.7%),外推性需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We aimed to compare cryoballoon pulmonary vein isolation (PVI) with standard radiofrequency cavotricuspid isthmus (CTI) ablation as first-line treatment for typical atrial flutter (AFL). METHODS: Cryoballoon Pulmonary Vein Isolation as First-Line Treatment for Typical Atrial Flutter was an international, multicentre, open with blinded assessment trial. Patients with CTI-dependent AFL and no documented atrial fibrillation (AF) were randomised to either cryoballoon PVI alone or radiofrequency CTI ablation. Primary efficacy outcome was time to first recurrence of sustained (>30 s) symptomatic atrial arrhythmia (AF/AFL/atrial tachycardia) at 12 months as assessed by continuous monitoring with an implantable loop recorder. Primary safety outcome was a composite of death, stroke, tamponade requiring drainage, atrio-oesophageal fistula, pacemaker implantation, serious vascular complications or persistent phrenic nerve palsy. RESULTS: Trial recruitment was halted at 113 of the target 130 patients because of the SARS-CoV-2 pandemic (PVI, n=59; CTI ablation, n=54). Median age was 66 (IQR 61-71) years, with 98 (86.7%) men. At 12 months, the primary outcome occurred in 11 (18.6%) patients in the PVI group and 9 (16.7%) patients in the CTI group. There was no significant difference in the primary efficacy outcome between the groups (HR 1.11, 95% CI 0.46 to 2.67). AFL recurred in six (10.2%) patients in the PVI arm and one (1.9%) patient in the CTI arm (p=0.116). Time to occurrence of AF of ≥2 min was significantly reduced with cryoballoon PVI (HR 0.46, 95% CI 0.25 to 0.85). The composite safety outcome occurred in four patients in the PVI arm and three patients in the CTI arm (p=1.000). CONCLUSION: Cryoballoon PVI as first-line treatment for AFL is equally effective compared with standard CTI ablation for preventing recurrence of atrial arrhythmia and better at preventing new-onset AF. TRIAL REGISTRATION NUMBER: NCT03401099.
引用
- Gupta D, Ding WY, Calvert P, et al. Cryoballoon Pulmonary Vein Isolation as First-Line Treatment for Typical Atrial Flutter. Heart. 2023. PMID: 36396438. doi:10.1136/heartjnl-2022-321729
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。